AnGes

AnGes EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of AnGes (4563.T) as of Oct 19, 2026 is -4.41. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.52 — a change of 74.88% (lower).

EV/EBIT

-4.41

YoY

74.88%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of AnGes is 2025 -4.41 . EV/EBIT (Enterprise Value to EBIT) of AnGes was 2024 -2.52 . It decreases by 74.88% lower compared to the previous year.

The AnGes EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-7.49 JPY
Jan 1, 2019
-7.02 JPY
Jan 1, 2020
-4.10 JPY
Jan 1, 2021
-1.47 JPY
Jan 1, 2022
-1.41 JPY
Jan 1, 2023
-1.92 JPY
Jan 1, 2024
-2.52 JPY
Jan 1, 2025
-4.41 JPY
The AnGes EV/EBIT history
YEAREV/EBITYoY
-4.41+74.88%
-2.52+31.39%
-1.92+36.32%
-1.41-4.20%
-1.47-64.18%
-4.10-41.60%
-7.02-6.27%
-7.49+7.28%
-6.98+44.85%
-4.82-12.41%
-5.50-45.50%
-10.09-28.68%
-14.15+241.79%
-4.14+60.47%
-2.58-61.72%
-6.74+5.97%
-6.36-92.40%
-83.70—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AnGes Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides AnGes's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates AnGes's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots AnGes's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if AnGes grows earnings faster than its peers.

AnGes Stock analysis

What does AnGes do? AnGes Inc is a Japanese biotechnology company specializing in the development and commercialization of therapies for cardiovascular, immunology, and oncology disorders. The company was founded in 1999 by experienced scientist Dr. Ryuichi Morishita. AnGes' technology is based on the use of DNA plasmids to deliver genes into human cells. This method offers a high level of control and precision in modifying genetic material, with the potential to revolutionize biotherapy. The company has conducted several successful clinical studies and acquired multiple patents related to their technology. Overall, AnGes operates in three main areas: cardiovascular medicine, oncology, and immunology. The company distributes a range of products and solutions for these fields, including therapies for heart failure, angina, cancer, and autoimmune diseases. AnGes' most well-known product currently is Collategene, used for the treatment of angina. Collategene is a therapy consisting of a combination of DNA plasmids and a special gel injected into the arteries. The gel promotes the formation of new blood vessels, supplying oxygen and nutrients to damaged tissue, supporting the repair and regeneration of the heart muscle. Another important product from AnGes is HGFgene, used to treat heart failure and chronic wounds. HGFgene contains essential growth factors that stimulate the formation of new blood vessels and tissue regeneration, potentially improving heart function. In addition to these products, AnGes also offers solutions for oncology, including a therapy called Protransgene used for pancreatic cancer treatment. Protransgene contains specific DNA plasmids that produce tumor-specific antigens and stimulate the body's immune system to fight the tumor. In immunology, AnGes has developed a technology called NFkB-decoy, with the potential to treat various inflammatory diseases such as rheumatoid arthritis, Crohn's disease, and ulcerative colitis. NFkB-decoy consists of synthetic DNA plasmids introduced into inflammatory cells, with anti-inflammatory effects. Overall, AnGes Inc. has established itself as a leading provider of biotherapeutics in Japan and is currently expanding into the US market. The company has an impressive track record in clinical research and development of innovative therapy options with the potential to improve the lives of millions of people. AnGes is one of the most popular companies on Eulerpool.

Frequently Asked Questions about AnGes stock

EV/EBIT (Enterprise Value to EBIT) of AnGes is -4.41 in 2025.

EV/EBIT (Enterprise Value to EBIT) of AnGes changed from -2.52 to -4.41, representing a 74.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) AnGes since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s AnGes with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — AnGes

All Key Metrics — AnGes